Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat

Brain Research

Volumn 739, Issue 1-2, 1996, Pages 70-78

  Shirayama, Yukihiko ^a,b,c   Mitsushio, Hiroshi ^a,b   Takashima, Mizuo ^a   Ichikawa, Hironobu ^a   Takahashi, Kiyohisa ^a,b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b National Center of Neurology and Psychiatry   (Japan)

^c Kanto Teishin Hospital   (Japan)

Author keywords

amygdala; antidepressant; striatum; substance P; substantia nigra

Indexed keywords

AMOXAPINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; IMIPRAMINE; MIANSERIN; SUBSTANCE P;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

AMOXAPINE; AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; CLOMIPRAMINE; CORPUS STRIATUM; DESIPRAMINE; IMIPRAMINE; MALE; MIANSERIN; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE P; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 0030580383     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00812-8     Document Type: Article

References (37)

1. [1] Arai, H., Moroji, T., Kosaka, K. and Iizuka, R., Extrahypophyseal distribution of α-melanocyte stimulating hormone (α-MSH)-like immunoreactivity in postmortem brains from normal subjects and Alzheimer-type dementia patients, Brain Res., 377 (1986) 305-310.
2. 2 binding sites in the frontal cortex of suicide victims and control subjects, Am. J. Psychiatry, 146 (1989) 730-736.
3. [3] Ballenger, J.C. and Post, R.M., Carbamazepine in manic-depressive illness: a new treatment, Am. J. Psychiatry, 137 (1980) 782-790.
4. [4] Bannon, M.J., Elliot, P.J. and Bunney, E.B., Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists, Mol. Brain Res., 3 (1987) 31-37.
5. [5] Barbaccia, M.L., Ravizza, L. and Costa, E., Maprotiline: an antidepressant with an unusual pharmacological profile, J. Phamacol. Exp. Ther., 236 (1986) 307-312.
6. [6] Barden, N., Daigle, M., Picard, V. and Di Paolo, T., Perturbation of rat brain serotonergic systems results in an inverse relation between substance P and serotonin concentrations measured in discrete nuclei, J. Neurochem., 41 (1983) 834-840.
7. [7] Biegon, A. and Israeli, M., Regionally selective increases in β-adrenergic receptor density in the brains of suicide victims, Brain Res., 442 (1988) 199-203.
8. [8] Brodin, E., Ogren, S.O. and Theodorsson-Norheim, E., Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P- and neurokinin A-/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat, Neuropharmacolgy, 26 (1987) 581-590.
9. [9] Brodin, K., Ogren, S.O. and Brodin, E., Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions, Eur. J. Pharmacol., 263 (1994) 175-180.
10. [10] Charney, D.S., Menkes, D.B. and Heninger, G.R., Receptor sensitivity and the mechanism of action of antidepressant treatment, Arch. Gen. Psychiatry, 38 (1981) 1160-1180.
11. [11] De Montis, G.M., Denovo, P., Gessa, G.L., Meloni, D., Porcella, A., Saba, P., Serra, P. and Tagliamonte, A., Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants, Eur. J. Pharmacol., 180 (1990) 31-35.
12. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
13. 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination, J. Neurochem., 62 (1994) 2262-2268.
14. 2 binding sites in the rat cerebral cortex, J. Neural Transm., 59 (1984) 9-23.
15. [15] Hamon, M., Gozlan, H., Bourgoin, S., Benoliel, J.J., Mauborgne, A., Taquet, H., Cesselin, F. and Mico, J.A., Opiod receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline, Neuropharmacology, 26 (1987) 531-539.
16. [16] Hanson, G.R., Alphs, L., Wolf, W., Levine, R. and Lovenberg, W. Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems, J. Pharmacol. Exp. Ther., 218 (1981) 568-574.
17. [17] Heilig, M. and Ekman, R., Chronic parenteral antidepressant treatment in rats: unaltered levels and processing of neuropeptide Y (NPY) and corticotropin-releasing hormone (CRH), Neurochem. Int., 26 (1955) 351-355.
18. [18] Heninger, G.R. and Charney, D.S. Mechanism of action of antidepressant treatment: implication for the etiology and treatment of depressive disorders. In H. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress Raven Press, New York, 1987, pp. 535-544.
19. [19] Hong, J.S. Yang, H.-Y.T. and Costa, E., Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs, Neuropharmacolgy, 17 (1978) 83-85.
20. [20] Hong, J.S., Tilson, H.A. and Yoshikawa K., Effects of lithium and haloperidol administration on the rat brain substance P, J. Pharmacol. Exp. Ther., 224 (1983) 590-593.
21. [21] Horovitz, Z.P., The amygdala and depression. In S. Garattini and M. Dukes (Eds.), Antidepressant Drugs, Excepta Medica, Amsterdam, 1966, pp. 121-129.
22. [22] Jones, R.S.G. and Olpe, H.-R., An increase insensitivity of rat cingulate cortical neurons to substance P occurs following withdrawal of chronic administration of antidepressant drugs, Br. J. Pharmacol., 81 (1984) 659-664.
23. [23] Kakigi, T., Maeda, K., Kaneda, H. and Chihara, K. Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain, J. Affect. Disord., 25 (1992) 215-220.
24. [24] Kato, N., Honda, Y., Ebihara, S., Naruse, H. and Takahashi, Y., Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs, Neuroendocrinology, 39 (1984) 39-44.
25. 3H]SCH23390 binding sites in the striatum and limbic system, Eur. J. Pharmacol., 139 (1987) 163-169.
26. [26] Kurumaji, A., Mitsushio, H. and Takashima, M. Chronic dietary treatment with antidepressants decrease brain Met-enkephalin-like immunoreactivity in the rat, Psychopharmacology, 94 (1988) 188-192.
27. [27] Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-276.
28. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims, Arch. Gen. Psychiatry, 43 (1986) 954-959.
29. [29] Mitsushio, H., Takashima, M., Mataga, N. and Toru, M., Effects of chronic treatment with trihexyphenidyl and carbamazepine alone or in combination with haloperidol on substance P content in rat brain: a possible implication of substance P in affective disorders, J. Pharmacol. Exp. Ther., 245 (1988) 982-989.
30. [30] Oblin, A., Zivkovic, B. and Bartholini, G., Involvement of the D-2 dopamine receptor in the neuroleptic-induced decreases in nigral substance P, Eur. J. Pharmacol., 105 (1984) 175-177.
31. [31] Okuma, T., Inagaki, K., Otsuki, S., Sarai, K., Takahashi, R., Hazama, H., Mori, A. and Watanabe, S., A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness, Psychopharmacology, 73 (1981) 95-96.
32. 125I-iodopindolol to β 1 adrenoceptors in the amygdala of rat after antidepressant treatments, J. Pharmacol. Exp. Ther., 257 (1991) 681-690.
33. [33] Richelson, E. and Pfenning, M., Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake, Eur. J. Pharmacol., 104 (1984) 277-286.
34. [34] Shaikh, M.B., Steinberg, A. and Siegel, A., Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat, Brain Res., 625 (1993) 283-294.
35. [35] Sonsalla, P.K., Gibb, J.W. and Hanson, G.R., Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation, Eur. J. Pharmacol., 105 (1984) 185-187.
36. [36] Tanda, G., Bassareo, V. and Di Chiara, G., Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat, Psychopharmacology, 123 (1996) 127-130.
37. [37] Wang, R.Y. and Aghajanian, K., Enhanced sensitivity of amygdaloid neurons to serotonin and norepinephrine after chronic antidepressant treatment, Commun. Psychopharmacol., 4 (1980) 83-91.